Literature DB >> 29367001

Comparison Between Posterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative Diseases: A Systematic Review and Meta-Analysis.

Tao Lan1, Shi-Yu Hu2, Yuan-Tao Zhang3, Yu-Chen Zheng1, Rui Zhang1, Zhe Shen1, Xin-Jian Yang4.   

Abstract

OBJECTIVE: To compare the efficacy and safety in the management of lumbar diseases performed by either posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF). Interbody fusion is considered the "gold standard" in the treatment of lumbar degenerative diseases. Both PLIF and TLIF have been advocated, and it remains controversial as to the best operative technique.
METHODS: The electronic databases including Embase, PubMed, and Cochrane library were searched to identify relevant studies up to September 2017. The primary outcomes were fusion rate, complications, and clinical satisfaction. The secondary outcomes were length of hospitalization, operation time, blood loss, postoperative visual analog scale, Oswestry Disability Index, and Japanese Orthopaedic Association Score. Data analysis was conducted with RevMan 5.3 software.
RESULTS: A total of 16 studies involving 1502 patients (805 patients in PLIF group and 697 in TLIF group) were included in the meta-analysis. The pooled analysis showed that there was no significant difference in terms of fusion rate (P > 0.05) and clinical satisfaction (P > 0.05) between the 2 groups. TLIF was superior to PLIF with significantly lower incidence of nerve root injury (P < 0.05) and dural tear (P < 0.05). However, there was no significant difference regarding wound infection (P > 0.05) and graft malposition (P > 0.05). PLIF required significant longer operation time (P < 0.05) and was associated with more blood loss (P < 0.05). Although TLIF was associated with better postoperative visual analog scale, Oswestry Disability Index, and Japanese Orthopaedic Association Score than PLIF, there was no statistical difference regarding these results.
CONCLUSIONS: The available evidence suggests that both TLIF and PLIF could achieve similar clinical satisfaction and fusion rate in the management of degenerative lumbar diseases. However, TLIF was superior to PLIF with shorter operation time, less blood loss, and lower incidence of nerve root injury and dural tear. There is no significant difference between both groups regarding wound infection and graft malposition.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Lumbar disease; Meta-analysis; Posterior lumbar interbody fusion (PLIF); Transforaminal lumbar interbody fusion (TLIF)

Mesh:

Year:  2018        PMID: 29367001     DOI: 10.1016/j.wneu.2018.01.021

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  19 in total

1.  History and Evolution of the Minimally Invasive Transforaminal Lumbar Interbody Fusion.

Authors:  Michael C Prabhu; Kevin C Jacob; Madhav R Patel; Hanna Pawlowski; Nisheka N Vanjani; Kern Singh
Journal:  Neurospine       Date:  2022-09-30

2.  Learning Curve and Initial Outcomes of Full-Endoscopic Posterior Lumbar Interbody Fusion.

Authors:  Renchun Tan; Xin Lv; Pengfei Wu; Yawei Li; Yuliang Dai; Bin Jiang; Bolin Ren; Guohua Lv; Bing Wang
Journal:  Front Surg       Date:  2022-04-28

3.  Bidirectional Expandable Technology for Transforaminal or Posterior Lumbar Interbody Fusion: A Retrospective Analysis of Safety and Performance.

Authors:  Domagoj Coric; Raphael R Roybal; Mark Grubb; Vincent Rossi; Alex K Yu; Isaac R Swink; Jason Long; Boyle C Cheng; Jason A Inzana
Journal:  Int J Spine Surg       Date:  2020-10-29

4.  [Comparative study on effectiveness of modified-transforaminal lumbar interbody fusion and posterior lumbar interbody fusion surgery in treatment of mild to moderate lumbar spondylolisthesis in middle-aged and elderly patients].

Authors:  Zhijie Yang; Bo Liu; Haiyang Lan; He Ye; Jie Chen; Huiqiang Xia; Ye Zhang; Fei Han
Journal:  Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi       Date:  2020-05-15

5.  Safety of Lumbar Interbody Fusion Procedures for Degenerative Disc Disease: A Systematic Review With Network Meta-Analysis of Prospective Studies.

Authors:  Kuan-Yu Chi; Shih-Hao Cheng; Yu-Kai Kuo; En-Yuan Lin; Yi-No Kang
Journal:  Global Spine J       Date:  2020-07-28

6.  Repeat decompression and fusions following posterolateral fusion versus posterior/transforaminal lumbar interbody fusion for lumbar spondylosis: a national database study.

Authors:  Moon Soo Park; Young-Su Ju; Seong-Hwan Moon; Tae-Hwan Kim; Jae Keun Oh; Jin Kyu Lim; Chi Heon Kim; Chun Kee Chung; Ho Guen Chang
Journal:  Sci Rep       Date:  2019-03-20       Impact factor: 4.379

7.  Clinical efficacy and radiographic K-rod stabilization for the treatment of multilevel degenerative lumbar spinal stenosis.

Authors:  Chaohua Fu; Tianjun Chen; Yuhao Yang; Hua Yang; Maohui Diao; Guowei Zhang; Zhisheng Ji; Hongsheng Lin
Journal:  BMC Musculoskelet Disord       Date:  2020-07-06       Impact factor: 2.362

8.  Analysis of clinical effect and radiographic outcomes of Isobar TTL system for two-segment lumbar degenerative disease: a retrospective study.

Authors:  Zhi-Sheng Ji; Hua Yang; Yu-Hao Yang; Shao-Jin Li; Jian-Xian Luo; Guo-Wei Zhang; Hong-Sheng Lin
Journal:  BMC Surg       Date:  2020-01-17       Impact factor: 2.102

9.  Efficacy of Biocage in treating single-segment lumbar degenerative disease in patients with high risk of non-fusion: a prospective controlled study with at least 2 years' follow-up.

Authors:  Yang Li; Yang Yu; Tian-Yong Hou; Ze-Hua Zhang; Jun-Chao Xing; Hong-Wei Lu; Rui Zhou; Peng Cheng; Jian-Zhong Xu; Wen-Jie Wu; Fei Luo
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

10.  A retrospective controlled study protocol of transforaminal lumbar interbody fusion compared with posterior lumbar interbody fusion for spondylolisthesis.

Authors:  Ping Yi; Xiangsheng Tang; Feng Yang; Mingsheng Tan
Journal:  Medicine (Baltimore)       Date:  2020-10-30       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.